An open label trial to investigate the relationship between plasma levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF) as a clinical response to duloxetine treatment in patients with major depressive disorder (MDD)

Trial Profile

An open label trial to investigate the relationship between plasma levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF) as a clinical response to duloxetine treatment in patients with major depressive disorder (MDD)

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2015

At a glance

  • Drugs Duloxetine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 26 Oct 2015 New trial record
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top